ClinicalTrials.gg
WithdrawnNCT02662894Updated Feb 24, 2021

Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.

A Phase 3 interventional study of Valsartan 160mg + Rosuvastatin 20mg and Valsartan 320mg + Rosuvastatin 20mg in Hypertension and Dyslipidemia, sponsored by EMS. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-02-24.

Sponsored by EMS · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
135th of 139
0 · median 198
Started
2019
the only one that year
Phase 3
53 of 140
none open now
Registered
127th of 140
by date

Among the 140 studies testing valsartan in Hypertension, this one is the 135th largest by enrollment of the 139 interventional ones that give a count, is the only one that started in 2019, is one of 53 in phase 3, and was the 127th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

Noninferiority trial to assess efficacy of fixed-dose combination of valsartan + rosuvastatin versus their isolated components in treatment of hypertension and dyslipidemia.

Read the detailed description
  • Open-label,randomized, multicenter;
  • Maximal experiment duration: 8 weeks;
  • 04 visits;
  • Safety and efficacy evaluation
03

Conditions studied

  • Hypertension
  • Dyslipidemia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants of both sexes aged between 18 and 65 years;
  • Participants diagnosed with uncontrolled hypertension;
  • Participants with intermediate and high risk dyslipidemia, according to the V Brazilian Guidelines on Dyslipidemia and Prevention of Atherosclerosis;
  • Ability to understand and consent to participate in this clinical study, manifested by signing the and Informed ( IC) .

Exclusion criteria

Exclusion Criteria:

  • Participants with a previous diagnosis of familial hypercholesterolemia (homozygous);
  • Concomitant use of angiotensin II receptor blocker (ARB) or inhibitor of angiotensin converting enzyme (ACE);
  • participants with isolated hypertriglyceridemia (TG ≥150 mg / dL) according to V Brazilian Guidelines on Dyslipidemia and Prevention of Atherosclerosis;
  • research participants with total cholesterol (TC) above 500 mg / dL or triglyceride (TG) above 400 mg / dL;
  • participants with systolic blood pressure ≥180 mmHg or diastolic ≥110 mmHg;
  • research participants with postural hypotension (SBP decrease ≥20 mmHg or DBP ≥10 mmHg in orthostatic position in relation to the sitting position);
  • History of congestive heart failure (CHF) functional class III or IV ();;
  • any clinical, laboratory and electrocardiographic that, in the judgment of the investigator, may interfere with the safety of research participants;
  • Creatine phosphokinase (CPK) levels above the established laboratory normal range;
  • Transaminases ( and ASL) serum above 2 times the established laboratory normal range;
  • (BMI) ≥35 kg / m²;
  • participants (eg .: , patients with Acquired Immunodeficiency Syndrome etc);
  • Chronic use of drugs that may interact with the drugs of the study;
  • Patients on concomitant lipid-lowering therapy;
  • History to the active ingredients used in the study;
  • Participants who are pregnant, nursing or planning to become pregnant, or female participants of who are not using a reliable method of ;
  • History of alcohol abuse or illicit drug use;
  • Adherence to uniformization medication \<80%;
  • Participating in the research that has participated in clinical trial protocols in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J), unless the investigator considers that there may be direct benefit to it;
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Valsartan 160mg + Rosuvastatin 20mg

    Fixed-dose combination of valsartan (160mg) + rosuvastatin (20 mg), oral, once daily.

    Drug: Valsartan 160mg + Rosuvastatin 20mg

  • Experimental
    Valsartan 320mg + Rosuvastatin 20mg

    Fixed-dose combination of valsartan (320 mg) + rosuvastatin (20 mg), oral, once daily.

    Drug: Valsartan 320mg + Rosuvastatin 20mg

  • Active comparator
    Diovan® 160mg + Crestor® 20mg

    Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.

    Drug: Diovan® 160mg + Crestor® 20mg

  • Active comparator
    Diovan® 320mg + Crestor® 20mg

    Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.

    Drug: Diovan® 320mg + Crestor® 20mg

Interventions

  • DrugValsartan 160mg + Rosuvastatin 20mg

    Drug page: Valsartan

    1 tablet, oral, a day

  • DrugValsartan 320mg + Rosuvastatin 20mg

    Drug page: Valsartan

    1 tablet, oral, a day

  • DrugDiovan® 160mg + Crestor® 20mg

    Drug page: Valsartan

    Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.

    Also known as: Valsartan 160mg + Rosuvastatin 20mg

  • DrugDiovan® 320mg + Crestor® 20mg

    Drug page: Valsartan

    Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.

    Also known as: Valsartan 320mg + Rosuvastatin 20mg

06

What researchers measure

Primary outcomes

  1. Reduction of systemic blood pressure measured between the first visit and last visit.

    Time frame: 8 weeks

  2. Percentage of participants who reach the goal of LDL-C according to intermediate risk rating ( LDLc < 100mg / dL ) and high risk ( LDLc < 70 mg / dL ) .

    Time frame: 8 weeks

Secondary outcomes

  1. Incidence and severity of adverse events recorded after the signing of the Informed Consent ( IC) and until the end of the study.

    Time frame: 8 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2019; primary completion for Sep 2020, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2015
First posted
Jan 26, 2016
StartEst.
Oct 2019
Primary completionEst.
Sep 2020
CompletionEst.
Dec 2020
Last update
Feb 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02662894
Lead sponsor
EMS
Responsible party
Sponsor
First posted
Jan 26, 2016
Start date
Oct 2019 (estimated)
Primary completion
Sep 2020 (estimated)
Completion
Dec 2020 (estimated)
Last update
Feb 24, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion